Search Results
10
Everything
Search Filters
Organization
Sonnet BioTherapeutics Holdings, Inc.
Sonnet Announces Release of Corporate Update Video
April 01, 2025 16:15 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs...
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
April 01, 2025 07:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs...
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
March 26, 2025 09:05 ET
|
Sonnet BioTherapeutics Holdings, Inc.
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy,...
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
March 19, 2025 08:50 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with...
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
March 11, 2025 08:45 ET
|
Sonnet BioTherapeutics Holdings, Inc.
On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage...
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
February 26, 2025 09:00 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain...
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
February 19, 2025 08:35 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC...
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
February 18, 2025 09:15 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
February 13, 2025 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
February 13, 2025 08:00 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and...